Mutations which perturb normal pre-mRNA splicing are significant contributors to human disease. 2
Introduction
Pre-mRNA splicing in humans is mediated by the major and minor spliceosomes, highly dynamic, 16 metalloenzyme complexes comprised of five key small nuclear RNAs (snRNA), along with over 100 17 protein components and accessory molecules (Brody and Abelson 1985; Hang et al. 2015 ; Scotti and 18 Swanson 2016). Accurate recruitment and function of the spliceosome is reliant on a plethora of cis-19 acting regulatory elements encoded within the pre-mRNA itself. Whilst our understanding of the 20 underlying mechanistic processes regulating splicing has greatly increased in recent years, our ability 21 to predict whether or not a mutation will affect splicing remains limited. However, with estimates 22 that up to 50% of monogenic disease-causing variants may affect splicing (Teraoka et al. 1999; Ars et 23 al. 2000) , a better understanding and more coherent approach to interpretation of variants affecting 24 splicing is badly needed (Cartegni et al. 2002 ; Baralle and Buratti 2017) . With a plethora of in silico 1 splicing pathogenicity predictors available, there is little consensus on what a "gold standard" for 2 splicing pathogenicity prediction would be (Houdayer et al. 2012; Jian et al. 2014b; Tang et al. 2016 ). 3 Whilst many of these methods perform well within the canonical splice site dinucleotides (CSS, the 4 two highly-conserved bases flanking the acceptor and donor sites), their utility for other splice 5 relevant regions is less clear (Tang et al. 2016 ). In the clinical setting, often multiple algorithms and 6 expert judgment are used to predict pathogenicity, while for large scale research projects, 7 classification of variants is often binary, with CSS mutations typically classified as likely splice 8 affecting, whilst mutations in other splicing regulatory components are typically overlooked (Iossifov 9 et al. 2014; Wright et al. 2015 ; Deciphering Developmental Disorders 2017). Previous attempts to 10 estimate the relative contribution of pathogenic variants at non-canonical splice sites were based on 11 collating diverse published datasets of pathogenic variants (Lewandowska 2013) or data submitted 12 to databases of clinically interpreted variation (Krawczak et al. 2007 ) and are therefore sensitive to 13 the inherent heterogeneity and biases of such data, especially given the inevitable subjectivity 14 involved in clinical interpretation of this class of variation. Both clinical and research interpretation 15 of potential splice-disrupting variants lacks a robust quantitative foundation. 16
Utilising large scale exome sequencing data from 13,750 unaffected parents recruited as part of the 17
Deciphering Developmental Disorders (DDD) project (Wright et al. 2015) and >60,000 aggregated 18 exomes from the Exome Aggregation Consortium (ExAC) (Lek et al. 2016 ), we explore selective 19 constraint around splice regions across a set of 148,244 stringently defined exons well covered 20 (median coverage >15X at both CSS) across the DDD cohort (see Methods). Since selection is driven 21 by a number of factors, including monogenic developmental disorders (DD), as a complementary, 22
disease-based approach, we analyse enrichment of de novo mutations (DNMs) in DDD probands in 23 the same regions. We provide an unbiased, exome wide view of the signatures of selection and the 24 relative contribution of pathogenic splice altering mutations between the CSS and other, near splice 25 positions. 26
Results

1
Signatures of purifying selection around the splice site 2
Since purifying selection acts to keep deleterious alleles rare, population variation data can be used 3 to identify and assess the relative strengths of signals of purifying selection. To assess selective 4 constraint acting on positions around the canonical splice site we used the Mutability Adjusted 5
Proportion of Singletons (MAPS) metric (Lek et al. 2016 ) (a measure for inferring the degree of 6 selection robust to local variance in mutation rate) in 13,750 unaffected parents enrolled in the DDD 7 study as well as >60,000 aggregated exomes from ExAC (Figure 1a ). The canonical splice acceptor 8 and donor dinucleotides show a clear signal of purifying selection in both datasets. 9
Outside of the CSS, other positions clearly show a signal of purifying selection beyond the 10 background level, including the donor site (last base of the exon, which is particularly pronounced 11 when the reference allele is G (Figure 1a 
Deficit of splicing variants in highly constrained genes in healthy individuals 20
We also examined the distribution of variants of different classes among genes that are known to be 21 under different levels of selective constraint. Highly constrained genes should contain fewer 22 deleterious variants than less constrained genes. We investigated the proportion of variants 23 observed in the 13,750 unaffected parents which fell within highly constrained genes (probability of 24 loss of function (LoF) intolerance (pLI, (Lek et al. 2016 )) > 0.9) in our splicing regions of interest 1 (Figure 1b ). In the near splice positions at which the highest MAPS values were seen (CSS, donor, 2 donor+5), we also observed a stronger depletion of variants in high pLI genes within the unaffected 3 parents, again supporting the potential pathogenicity of variants at these positions. The proportion 4 of parental variants in high pLI genes also recapitulates the signals of purifying selection seen in the 5 MAPS analyses with regard to the donor position split by reference allele (Figure 1b A. Selective constraint across splicing region in 13,750 unaffected parents of DDD probands and >60,000 aggregated exomes from ExAC. Mutability adjusted 2 proportion of singletons (MAPS) with 95% confidence intervals (CI) shown for Ensembl's Variant Effect Predictor (VEP) annotated exonic sites, extended 3 splice acceptor and splice donor regions, the last base of the exon, split by reference nucleotide, and grouped sites in the polypyrimidine tract region 4 (PolyPy), split by changes from a pyrimidine to a purine (PyPu) vs all other changes. B. Proportion of variants with 95% CI in 13,750 unaffected parents of 5 DDD probands which fall within genes with high probability of loss of function intolerance (pLI >0.9) across VEP annotated exonic sites, extended splice 6 acceptor and splice donor regions, the last base of the exon, split by reference nucleotide, and grouped sites in the polypyrimidine tract region, split by 7 changes from a pyrimidine to a purine (PyPu) vs all other changes. Lower panel shows splice acceptor and splice donor consensus sequences, based on our 8 exons of interest. 
Estimating positive predictive values for different classes of splice mutation 1
We used the fold-enrichment of the numbers of observed DNMs in dominant DD genes in the DDD 2 cohort over the number expected under the null mutation model to calculate positive predictive 3 values (PPVs) for groupings of near splice site positions. We compared these with PPVs for other, 4 more commonly disease-associated variant classes within the same exons of the same genes ( Figure  5 2c). We observe minor differences in PPV for the individual positions of the canonical acceptor and 6 donor sites, with don+2 showing the lowest PPV at 0.90, which is approximately the same as for the 7 don+5 position (PPV 0.89). Variants within the PolyPy region which change a pyrimidine for a purine 8 have a PPV of 0.71, which is below the PPV for missense mutations (0.79), but still predicts a 9 substantive number of pathogenic mutations arising from disruption of the PolyPy. 10
Despite the modest number of observed DNMs used to make these PPV estimates, we see striking 11
concordance with the population based metrics described above (MAPS and deficit of splicing 12 variants in high pLI genes in unaffected parents of DDD patients -Supplemental Fig. S3 ), suggesting 13 these estimates are robust. blinded to the precise mutation and PPVs estimated above, and the patient's recruiting clinician, to 5 assess the phenotypic similarity between the proband and the disorder expected from a LoF 6 mutation in that gene. The 38 variants were classified as likely diagnostic (Table 1) , or unlikely 7 diagnostic/unknown ( Supplemental Table S1 ), depending on the strength of phenotypic similarity. 8
Phenotypic information for probands with likely diagnostic variants is given in Supplemental Table  9 S2, and pathogenicity prediction scores for the SNVs in Supplemental Table S3 . The clinical review 10 resulted in 18 variants (47%) being classified as likely diagnostic, highly concordant with the number 11 predicted from the overall PPV of non-canonical sites of 46%, moreover, a higher proportion of likely 12 diagnostic variants were classified at sites with higher PPVs (Pearson's correlation coefficient = 0.91, 13 p = 0.033) ( Figure 3 ). With 48 CSS DNMs observed within the same exons in our probands, we 14 estimate that 73% (95% CI: 60-82%) of disease causing splice disrupting DNMs occur within the CSS, 15 while 27% (95% CI: 18-39%) are in non-canonical, near-splice positions. 16
Eight DNMs were selected for functional validation via a minigene vector system, including six likely 17 diagnostic PolyPy variants, a PolyPy variant of uncertain clinical significance, and a likely diagnostic 18 don+5 variant, where both the phenotype of the patient and that associated with the gene (MBD5)  19 are nonspecific, along with two negative controls (untransmitted variants identified in unaffected 20 parents within the same PolyPys as test variants). For six of the variants selected for validation, 21 differences in splicing between the reference and mutant constructs were observed (Supplemental 22 Fig. S4a and S4b). One of the likely diagnostic PolyPy mutations, the PolyPy mutation of uncertain 23 significance, and both negative controls showed no difference in splicing between the reference and 24 mutant constructs (Supplemental Fig. S4c and S4d). 25 
Assessing splicing pathogenicity prediction tools 1
The population genetic metrics of purifying selection and mutation enrichment metric for 2 pathogenicity that we have derived provide an orthogonal approach to assessing the accuracy of 3 splicing pathogenicity prediction tools, compared to the standard approach of assessing 4 classification accuracy for clinically interpreted variants. We assessed four splicing pathogenicity 5 We divided the scores from each prediction tool, plus CADD (Kircher et al. 2014 ), into 20 equal-sized 9 bins to facilitate cross-method comparability. We calculated the MAPS for each bin of each of the 10 scoring metrics for the splicing variants observed in the 13,750 DDD unaffected parents, and saw a 11 strong positive correlation between pathogenicity metric and MAPS for all tools (Figure 4 ). AdaBoost 12 had the highest absolute MAPS value for the top scoring bin, suggesting that it is best able to identify 13 variants under the strongest purifying selection. The proportion of variants in the unaffected parents 14 falling in genes with pLI > 0.9 broadly recapitulates this pattern, with fewer variants in high pLI genes 15 in the highest scoring brackets for all metrics (Supplemental Fig. S5 ). We then looked at the 16 distribution of scores for each tool for the 83 splicing DNMs observed in DDD probands in autosomal 17 dominant DD-associated genes which were covered by all five scoring systems to compare 18 performance of the metrics on mutations more likely to have a deleterious impact on splicing, with 19 the expectation that these potentially damaging variants would be scored highly by the metrics, 20
giving high values of area under the curve (AUC, Figure 5 ). Again, all metrics performed well, with 21 the majority of DNMs being classified in the most deleterious score brackets. Here AdaBoost gave 22 the highest AUC value, suggesting it weighted these likely damaging variants as more deleterious 23 than the other metrics comparatively. Interestingly, when CSS positions were removed from the 24 analysis, AdaBoost remained the tool with the highest AUC. The largest reduction in the AUC metric 25 was seen for Spidex and CADD, indicating these tools may be least informative for positions outside 1 of the CSS. Upon removal of the CSS positions from the analyses of MAPS and deficit of parental 2 variants in high pLI genes, similar results were revealed, with the highest AdaBoost scores retaining 3 strong signals of purifying selection but a marked reduction in signal from the highest Spidex scores 4 (Supplemental Fig. S6 and Supplemental Fig. S7 ). 5
Taken together, these data show a strong relationship between the considered splicing 6 pathogenicity scoring systems and the general landscape of purifying selection on splicing control, 7 but demonstrate that the utility of these systems in identifying likely diagnostic variants is limited 8 outside of the CSS. 9 intronic splicing enhancers and silencers are currently unavailable, algorithms that predict the 14 impact of mutations at such sites are not highly accurate, and some of these sites are not covered by 15 exome sequencing (the greater utilisation of whole genome sequencing will allow greater 16 opportunity to find and assess the contributions of more distal splice disrupting variants). As such, 17 our estimate of the contribution of non-canonical splicing position mutations is likely to be a lower 18 bound. Thus our estimate of 35-40% under-ascertainment in clinical databases may be conservative, 19 and the true extent of missed diagnoses may be even higher. 20
The size of the available datasets determines our power to detect signals of selection and 21 enrichment of DNMs, so although we could demonstrate signal at splice-important non-canonical 22 positions, there may be other positions with more subtle signals of selection which we lacked the 23 power to detect with current sizes of datasets. Collation of yet larger datasets will help to identify 24 these sites, using the same methodology applied here. 25
The nature of many developmental disorders makes obtaining RNA samples from relevant tissues of 1 patients (i.e. neural tissue) acutely problematic, so we investigated the effects on splicing of several 2 of the potentially diagnostic DNMs using a minigene vector system. We were able to demonstrate 3 changes to splicing for five out of six likely diagnostic PolyPy variants as well as the likely diagnostic 4 don+5 variant, supporting the clinical interpretation based on clinical phenotype. We did not definitively state that the effects seen in the minigene assay would be the same in the full genetic, 11 developmental and cellular context within the patient. 12 We envisage that greater appreciation of the importance of near splice site mutations will increase 13 diagnostic yields, as well as providing increased power for the detection of new genetic associations, 14 both within the field of rare disease and beyond. We highlight two challenges to improving detection 15 of pathogenic non-canonical splice site mutations. 16
First, many commonly used in silico tools for annotating the likely functional impact of variants do 17 not discriminate between different non-CSS positions with very different likelihoods of being Second, current tools that predict the pathogenicity of non-CSS mutations have limited accuracy, 7
and it is not clear how to translate the scores that they output into a likelihood of pathogenicity. The 8 quantitative framework that we introduced here of estimating PPVs for different classes of 9 mutations by comparing the number of observed mutations to the number expected under a well-10 calibrated null model of germline mutation has much more direct relevance to clinical 11 interpretation, although the interpretation of specific DNMs still proves problematic, particularly for 12
DNMs in sites of intermediate PPV. We propose that the scores generated by such splicing 13 prediction tools could be calibrated by performing analogous analyses of mutation enrichment to 14 estimate PPVs for different bins of scores. As the size of trio-based cohorts increases, the accuracy of 15 calibration will improve. 16
In summary, our results demonstrate a significant contribution of non-canonical splicing mutations 17 to the genetic landscape of DDs, a finding which is highly likely to be recapitulated across other 18 monogenic disorders and contexts. We demonstrate the importance of non-canonical positions 19 (particularly the don+5 site and pyrimidine-removing mutations in the PolyPy region). These 20 inferences are supported by both population genetic investigations of purifying selection, as well as 21 a disease based approach, considering the burden of DNMs in ~8,000 children with severe DDs. 22
Mutations at some non-canonical splicing positions convey a risk of disease similar to that of protein 23 truncating and missense mutations, but are under-represented in existing databases of disease-24 causing variants. 25 
Materials and methods
Defining exons of interest 19
We took exons from gencode v19 (https://www.gencodegenes.org/releases/19.html) which met the 20 following criteria: annotation_type = "exon", gene_type = "protein_coding", gene_status = 21 "KNOWN", transcript_type = "protein_coding", transcript_status = "KNOWN", annotation != "level 22
3" (automated annotation), and tag = "CCDS", "appris_principal", "appris_candidate_longest", 23 "appris_candidate", or "exp_conf" (n = 255,812 exons) (Harrow et al. 2012 ). We removed a small 24 subset of exons which no longer met these criteria in the more recent, GRCH38 based gencode v22 25 release (leaving 253,275 exons). We removed any exons where the median coverage at the 1 canonical acceptor or donor positions was <15X in two sets of DDD data which used different exon 2 capture methods (Agilent Human All-Exon V3 Plus with custom ELID C0338371 and Agilent Human 3
All-Exon V5 Plus with custom ELID C0338371). 148,244 exons passed these criteria. 4
We annotated individual genomic positions relative to the acceptor and donor sites, removing any 5 exons <14bp, and any positions which had multiple potential annotations. At the acceptor end, we 6 considered 25bp of intronic sequence (acc-25 to acc-1) and 11bp exonic sequence (acc to acc+10). At 7 the donor end, we considered 10bp of intronic sequence (don+1 to don+10) and 11bp exonic 8 sequence (don to don-10). This yielded ~6.9 million near-splice positions of interest. 9
The reference nucleotide composition at each position of the splicing region of interest was 10 calculated using all sites and a weighted position weight matrix graph was generated using the 11 We define the PolyPy region as acc-3, and acc-5 to acc-17, based on pyrimidine content > 70% in our 14 exons of interest. We assess changes from a pyrimidine to a purine (PyPu) adjusting for the strand 15 the exon is on. 16
Mutability adjusted proportion of singletons (MAPS) 17
In 13,750 unaffected parents enrolled as part of the DDD study, as well as >60,000 aggregated 18 exomes from ExAC v0.3.1 (http://exac.broadinstitute.org/), we calculated the MAPS metric (Lek et al. 19 2016) using code developed in house by Patrick J. Short (https://github.com/pjshort/dddMAPS). The 20 MAPS metric is based on the principle that negative selection acts to keep deleterious variation rare 21 at a population level, but more mutable sequence contexts can contain variants that appear more 22 common because of recent recurrent mutational events, so the metric corrects frequencies based 23 on local sequence context using synonymous mutations. Only relevant ExAC sites with "PASS" in the 24 VCF "FILTER" column were counted, and ExAC and DDD variants were filtered for FisherStrand (FS) 1 <10. MAPS was calculated for all SNVs overlapping out splice positions of interest (201,587 near 2 splice variants for DDD, and 678,241 for ExAC), the last base of the exon split by reference 3 nucleotide (2109 variants for DDD, 6325 for ExAC), and the PolyPy, split by PyPu (15, method was run with 1000 iterations. 10
Parental variants in high pLI genes 11
We annotated all variant sites used in the MAPS calculations above in the 13,750 DDD parents with 12 the gene in which the variant fell, and the pLI score of that gene, and calculated the proportion of 13 these sites which fell within genes with high pLI scores (Lek et al. 2016 ) (> 0.9). 14
De novo mutations 15
DNMs were identified using DeNovoGear (Ramu et al. 2013 for this correction are based on the relationship between observed and expected synonymous 23
DNMs at different levels of coverage. We stratified this analysis into known dominant, known 24 recessive and non-DD associated genes using the DDG2P gene list 1 (http://www.ebi.ac.uk/gene2phenotype), downloaded in January 2016. Genes with recessive and 2 dominant modes of inheritance were restricted to the recessive list (see Supplemental Table S4) The proportion of CSS to non-CSS splicing diagnoses was calculated, along with 95% CIs, based on 18 5 non-CSS diagnoses and 48 CSS diagnoses in the same regions using the prop.test package in R 6 (version 3.4.4). 7
Validation of putative splicing variants 8
Eight variants were selected for validation via a minigene vector system. These comprised six likely 9 diagnostic variants from the PolyPy, a PolyPy variant of uncertain clinical significance, and a likely 10 diagnostic don+5 variant. Additionally, two untransmitted variants identified in unaffected parents 11 within the same PolyPys as test variants were selected as negative controls. Details of all variants 12 selected for validation are shown in Supplemental Table S5 . 13
Cloning splicing vectors 14
The minigene splice assay vector was adapted from that used in Singh et al. (Singh et al. 2016 ), by 15 replacing intron 1 with the first intron from the rat insulin 2 gene (Ins-2)(Rnor_6.0 Chr1:215857148-16 215857695). To generate individual assay vectors, either the 5' most 231bp (for the don+5 variant) 17 or the 3' most 274bp (for PolyPy variants) of this vector was replaced with the appropriate 18 endogenous intronic sequence encompassing the DNM of interest ( Figure S4a and S4b), as described 19 below. Between 114 and 202bp flanking endogenous intronic sequence was included, along with 20 6bp local exonic sequence from the gene of interest. 21
First, proband genotypes ( Supplemental Table S5 ) were verified by capillary sequencing of genomic 22 PCR products ( Supplemental Table S6 ). Genomic regions containing the reference and alternate 23 sequences were then either amplified by nested PCR, generated by site directed mutagenesis, or 24 generated using gene synthesis (IDT). These fragments were sub-cloned, by Gibson Assembly (NEB), 1 into our minigene vector ( Supplemental Table S7 , Supplemental Table S8 ). The regions assayed in 2 our vectors are detailed by genomic coordinates in Supplemental Table S5 . 3
In vitro splicing assay 4
HeLa cells were seeded into 12-well plates at a density of 160,000 cells per well, grown for 24 hours 5 and transfected with 1 microgram of plasmid vector using Lipofectamine 3000 (Invitrogen). All 6 transfections were carried out in duplicate and cultured for 48 hours. HeLa cells were cultured in 7 DMEM (10% FCS + 1% pen/strep) at 37C in a humidified incubator. Total RNA was extracted using a 8
Micro RNeasy Qiagen kit and mRNA converted into cDNA using superscript IV (Invitrogen). RT-PCR 9 was carried out using primers designed to span from exon 1 to exon 2, exon 2 to exon 3 and exon 1 10 to exon 3 and amplified on a thermocycler for either 25 or 35 cycles ( Supplemental Table S9 ). 11
Amplicons were capillary sequenced (GATC). For amplicons showing more than one splice variant 12 (mixed capillary traces, for CHD7-Alt and MBD5-Alt), we cloned the PCR amplicons (Zero Blunt PCR  13 cloning kit, Invitrogen) and sequenced individual colonies by capillary sequencing to identify the 14 splice variants present ( Supplemental Table S10 ). 15
Chromatograms were generated in R from .ab1 files using the sangerseqR ( 
Splicing pathogenicity scores 22
Since our region of interest spanned >6 million individual positions, each with three potential single 23 nucleotide changes, we were restricted in the choice of splicing pathogenicity prediction tools we 24 could utilise, as many function primarily through a low throughput web interface model. We interest. We also utilised the longer standing, and widely used MaxEntScan (MES)(Yeo and Burge 10 2004), for which perl scripts were available, allowing the tool to be run locally for all alternative 11 alleles of all positions of interest. The metric used for MES was the percent difference between the 12 scores for the reference and alternative alleles, with the greatest reduction in score classed as most 13 pathogenic. All sites were also scored with CADD (Kircher et al. 2014 ). 14 To allow cross-tool comparison, we ordered positions by increasing pathogenicity from each metric, 15 and split positions into 20 brackets, such that the cumulative triplet based mutation rate for all 16 variants in each bracket was equal, and the 20 th bracket contained the positions with the most 17 pathogenic scores. We calculated MAPS and the proportion of parental variants falling in high pLI 18
genes for each bracket for all five metrics, as above, and looked at the number of DNMs in known 19 dominant genes which fell in each bracket for the five metrics. Each of these analyses was conducted 20 including and excluding CSS dinucleotide positions. 21
Splice region variants in the ClinVar database 22
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